权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Study on a New Method for Autologous Blood Transfusion Using Recombinant Human Erythropoietin

重组人促红细胞生成素自体输血新方法的研究

基本信息

批准号：
02670555
负责人：
MAEDA Hiroo
金额：
$ 1.22万
依托单位：
Saitama Medical School
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1990
资助国家：
日本
起止时间：
1990 至 1991
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-02670555/
关键词：
Autologous blood transfusion Recombinant human erythropoietin Post-transfusion hepatitis

项目摘要

To avoid the side effects by homologous blood transfusion, we conducted predeposit autologous blood transfusion in patients undergoing orthopedic surgery with or without use of recombinant human erythropoietin (rHu-EPO). The patients not given rHu-EPO donated 400 ml of blood weekly for 3 weeks, a total of 1, 200 ml, before operation, unless the hemoglobin (Hb) value was less than 11.0 g/dl (the control group). In the same protocol, the patients given rHu-EPO (Chugai Pharmaceutical, Tokyo) twice or thrice a week for 4 weeks before operation also donated 1, 200 ml of autologous blood (the EPO 2/W and EPO 3/W groups). Ten of 12 patients in the control group succeeded in donating 1, 200 ml of blood, but the Hb value of 13.8 g/dl at predonation dropped to 10.9 g/dl after 1, 200 ml donation. All patients in the EPO group donated 1, 200 ml of blood and the Hb values of 13.0 g/dl and 12.7 g/dl in the EPO 2/W and 3/W groups at predonation only slightly decreased to 12.0 g/dl and 12.0 g/dl after donation, respectively. The decreased Hb value of 2.9 g/dl in the control group was significantly greater than those of the EPO group (1.0 g/dl in the EPO 2/W and 0.7 g/dl in the EPO 3/W group). The postoperative nadir of the Hb value in the control group was 8.0 g/dl and three patients in the control required homologous transfusion. The nadir of the Hb values in the EPO 2/W and 3/W group was 9.2 and 10.0 g/dl, respectively and none required homologous blood transfusion. rHu-EPO was efficacious in preventing the donor/patients from anemia induced by donations and useful in avoiding homologous blood transfusion.

为了避免异体输血的副作用，我们对骨科手术患者进行了预存自体血回输，并使用或不使用重组人促红细胞生成素（rHu-EPO）。未使用rHu-EPO的患者术前每周献血400 ml，共1200 ml，连续3周，除非血红蛋白（Hb）值低于11.0 g/dl（对照组）。在相同的方案中，患者在手术前每周给予rHu-EPO（中外制药，东京）两次或三次，持续4周，还捐献了1200 ml自体血（EPO 2/W和EPO 3/W组）。对照组12例患者中有10例成功献血1200 ml，但献血前Hb值为13.8 g/dl，献血1200 ml后降至10.9 g/dl。EPO组的所有患者捐献了1，200 ml血液，EPO 2/W和3/W组的Hb值在献血前分别为13.0 g/dl和12.7 g/dl，仅在献血后分别轻微降至12.0 g/dl和12.0 g/dl。对照组Hb值下降2.9 g/dl，显著大于EPO组（EPO 2/W组为1.0 g/dl，EPO 3/W组为0.7 g/dl）。对照组的Hb值术后最低值为8.0 g/dl，对照组中有3例患者需要异体输血。EPO 2/W和3/W组的Hb值最低值分别为9.2和10.0 g/dl，均不需要输异体血。rHu-EPO可有效预防供者/受者因献血引起的贫血，避免异体输血。